Inventor · disambiguated record
Maureen Kay Reilly
Also filed as: REILLY MAUREEN · REILLY MAUREEN KAY
24 granted patents·16 pending applications·123 citations·filing 2015–2024
95Inventor score
Files withPLIANT THERAPEUTICS INC11RAPT THERAPEUTICS INC9FLEXUS BIOSCIENCES INC7BRISTOL MYERS SQUIBB CO5DICE ALPHA INC3
Top patents by PatentIndex Score
40 records- 0196US10793564B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2019·Granted Oct 6, 2020·25 cites·69 claims
- 0296US9643972B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted May 9, 2017·15 cites·47 claims
- 0396US9598422B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Mar 21, 2017·21 cites·34 claims
- 0495US11560376B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·6 cites·79 claims
- 0594US11180494B2Substituted amino acids as integrin inhibitorsPLIANT THERAPEUTICS INC·Filed 2019·Granted Nov 23, 2021·11 cites·47 claims
- 0694US10683280B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2019·Granted Jun 16, 2020·8 cites·22 claims
- 0793US11384064B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Granted Jul 12, 2022·3 cites·28 claims
- 0893US10106546B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2017·Granted Oct 23, 2018·6 cites·66 claims
- 0992US11192879B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Granted Dec 7, 2021·3 cites·28 claims
- 1091US10246462B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Apr 2, 2019·10 cites·77 claims
- 1190US10179787B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Jan 15, 2019·5 cites·38 claims
- 1289US10533014B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2018·Granted Jan 14, 2020·3 cites·20 claims
- 1388US11858931B2Amino acid compounds with unbranched linkers and methods of usePLIANT THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·1 cites·54 claims
- 1487US10604526B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·2 cites·25 claims
- 1586US11952376B2Substituted amino acids as integrin inhibitorsPLIANT THERAPEUTICS INC·Filed 2021·Granted Apr 9, 2024·1 cites·172 claims
- 1686US11396506B2Amino acid compounds with unbranched linkers and methods of usePLIANT THERAPEUTICS INC·Filed 2019·Granted Jul 26, 2022·3 cites·33 claims
- 1784US2025223288A1Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1883US2025059167A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1981US2024199620A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2077US12098139B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2022·Granted Sep 24, 2024·0 cites·24 claims
- 2177US2024270742A1Substituted amino acids as integrin inhibitorsPLIANT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2277US2024294520A1Amino acid compounds with unbranched linkers and methods of usePLIANT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2377US2023271960A1Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2472US2022127233A1Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2570US11919863B2Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·17 claims
- 2669US12421195B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 23, 2025·0 cites·12 claims
- 2766US11932601B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2021·Granted Mar 19, 2024·0 cites·17 claims
- 2866US2020239480A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2963US11236049B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 1, 2022·0 cites·4 claims
- 3061US11236048B2Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 1, 2022·0 cites·16 claims
- 3161US2025313535A1Alpha 4 beta 7 integrin modulators and uses thereofDICE MOLECULES SV INC·Filed 2023·Application pending·0 cites
- 3260US2025177383A1Di-cyclopropyl based il-17a modulators and uses thereofDICE ALPHA INC·Filed 2023·Application pending·0 cites
- 3358US2024376056A1Phenyl acetamide based il-17a modulators and uses thereofDICE ALPHA INC·Filed 2022·Application pending·0 cites
- 3457US11242319B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Feb 8, 2022·0 cites·23 claims
- 3557US2025346602A1Lactam substituted imidazopyridazine il-17a modulators and uses thereofDICE ALPHA INC·Filed 2023·Application pending·0 cites
- 3656US10206893B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2017·Granted Feb 19, 2019·0 cites·23 claims
- 3755US2023181546A1Treatment of respiratory diseases with amino acid compoundsPLIANT THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3850US2023060422A1Combination treatment of liver diseases using integrin inhibitorsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3949US2023055657A1Combination treatment of liver diseases using integrin inhibitorsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 4048US2021317134A1Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →